Matthew N. Brams' trial period at Cingulate extended to Sep 30, 2026

Cingulate extended Matthew N. Brams' Trial Period as Executive Vice President and Chief Medical Officer to September 30, 2026.Original SEC Filing: Cingulate Inc. [ CING ] - 8-K - Jul. 02, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with t…

Cingulate extended Matthew N. Brams' Trial Period as Executive Vice President and Chief Medical Officer to September 30, 2026.

IndividualMatthew N. Brams

RoleExecutive Vice President and Chief Medical Officer

Type of ChangeAmendment to employment agreement (Trial Period extended)

Effective DateAmendment entered June 30, 2026; effective January 1, 2026; Trial Period extended to September 30, 2026

ReasonNot disclosed

Replacement InfoNot disclosed

Background DetailsNot disclosed beyond current role

Board/Committee Role ChangesNot disclosed

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.